EXTON, Pa--8 Nov--PRNewswire-AsiaNet/InfoQuest Melior Discovery, Inc. announced today that it has signed a research collaboration with Merck & Co., Inc. to evaluate the activity of select Merck neuroscience compounds utilizing elements of Melior's in vivo Indication Discovery platform. Under the terms of the agreement Merck will pay undisclosed fees for priority access to aspects of Melior's exclusively licensed platform. “Our agreement represents a significant opportunity for both Merck and Melior,” said Andrew Reaume, Ph.D., President and CEO of Melior. “Merck is gaining access to a unique in vivo testing platform and this agreement validates Melior’s Indication Discovery platform capabilities. We look forward to a productive collaboration.” Melior Discovery Overview Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique Indication Discovery platform of multiplexed in vivo models. It is using this capability to both build an internal pipeline of development candidates as well as sharing this capability with pharma and biotechnology company partners. In the former case, the Company is identifying“privileged” compounds that have been discontinued by others which it identifies through a close working relationship with Dr. Christopher Lipinski. in its partnered arrangements, Melior offers pharmaceutical partners an effective approach to expand their late-stage pipelines with safe, high-quality drug candidates that originated from internal R&D efforts. Melior Discovery is located in Exton, PA. For more information contact: Andrew Reaume President & CEO Melior Discovery 860 Springdale Drive Exton, PA 19341 e-mail: [email protected] Tel: (610) 280-0633 SOURCE: Melior Discovery, Inc. CONTACT: Andrew Reaume President & CEO, Melior Discovery +1-610-280-0633 [email protected] Web site: http://www.meliordiscovery.com --Distributed by AsiaNet ( www.asianetnews.net )--